Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8119602 | MERCK SHARP DOHME | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
Mar, 2027
(2 years from now) | |
US7772178 | MERCK SHARP DOHME | Pharmaceutical formulations and methods of treatment using the same |
Nov, 2027
(3 years from now) |
Victrelis is owned by Merck Sharp Dohme.
Victrelis contains Boceprevir.
Victrelis has a total of 3 drug patents out of which 0 drug patents have expired.
Victrelis was authorised for market use on 13 May, 2011.
Victrelis is available in capsule;oral dosage forms.
Victrelis can be used as treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food, treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease.
Drug patent challenges can be filed against Victrelis from 14 May, 2015.
The generics of Victrelis are possible to be released after 11 November, 2027.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
New Patient Population(NPP) | Feb 13, 2016 |
M(M-126) | Feb 27, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...
Dosage: CAPSULE;ORAL